A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma
复制标题
DOI：
10.1182/blood-2009-04-217521
复制
发表时间：
2009-09-24
期刊：
影响因子：
20.3
通讯作者：
Rothman, Nathaniel
中科院分区：
文献类型：
--
作者：
Purdue, Mark P.;Lan, Qing;Rothman, Nathaniel
最近一项针对 HIV(+) 患者的研究表明，诊断前血清可溶性 CD30 (sCD30) 浓度（慢性 B 细胞刺激的标志物）与患艾滋病相关非霍奇金淋巴瘤 (NHL) 的风险增加有关。为了在健康人中调查血清 sCD30 是否与 NHL 风险相关，我们在前列腺癌、肺癌、结直肠癌和卵巢癌筛查试验中进行了一项巢式病例对照研究。在 234 例病例和 234 名单独匹配的对照中，诊断前 sCD30 浓度与 NHL 风险之间存在很强的剂量反应关系（第二、第三和第四四分位数与第一四分位数的比值比 [95% 置信区间]：1.4 [0.8-2.6]、2.2 [1.2-4.1]、4.1 [2.2-7.8]；P（趋势）< .001），在提供血样 6 至 10 年后诊断的病例中仍然存在。鉴于在 HIV（+）患者中观察到类似的关系，我们的研究结果表明，慢性 B 细胞刺激可能是严重免疫功能低下和健康人群中 B 细胞淋巴瘤发生的重要机制。 （血。2009；114：2730-2732）
Prediagnostic serum concentration of soluble CD30 (sCD30), a marker for chronic B-cell stimulation, has been associated with increased risk of developing AIDS-related non-Hodgkin lymphoma (NHL) in a recent study of HIV(+) patients. To investigate among healthy persons whether serum sCD30 is associated with NHL risk, we carried out a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. There was a strong dose-response relationship between prediagnostic sCD30 concentration and NHL risk among 234 cases and 234 individually matched controls (odds ratio [95% confidence interval] for second, third, and fourth quartiles vs first quartile: 1.4 [0.8-2.6], 2.2 [1.2-4.1], 4.1 [2.2-7.8]; P(trend) < .001), which persisted among cases diagnosed 6 to 10 years after providing a blood sample. Given that a similar relationship has been observed among HIV(+) patients, our findings suggest that chronic B-cell stimulation may be an important mechanism involved in B-cell lymphomagenesis among severely immunocompromised and healthy populations alike. (Blood. 2009; 114: 2730-2732)